BTOG

British Thoracic Oncology Group (BTOG) - multi-disciplinary group for professionals involved with thoracic malignancies.

[ASCO @ASCO]

Our new living guideline Therapy for Stage IV NSCLC With Driver Alterations emphasizes broad NGS & IHC (PD-L1, HER2, MET) prior to frontline therapy. Comprehensive profiling is linked to ⬆️ OS & cost-effectiveness in Stage IV NSCLC: https://t.co/Z9UhEY3zdi
#LungCancer #NSCLC

[BTOG @BTOGORG]

From conferences to webinars—your feedback helps shape it all.
Complete the BTOG 2026 Membership Survey today.
👉 https://t.co/MdTXf9O458

[Dr Riyaz Shah @DrRiyazShah]

WU-KONG28: EGFR Ex20ins 1st line sunvo vs chemo; Meets PFR ORR DOR; Xover was allowed and 90% did in chemo arm; dose reductions in 40%, discontinuation 7%: #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

CHRYSALIS-2 cohort C: Ami Laz in atypical EGFR first line ; N49; ; 57% ORR; DoR 20.7m PFS 19.5m; mOS 41m👍🏽; Mutational subtype and compound status didn’t predict benefit in subgroups. The mOS probably defines the new gold standard #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

Should asymptomatic brain mets await systemic response in front line within EGFR/ALK context? I think yes. Despite reducing icPD, delayed brain RT OS looked better and radiation necrosis didn’t occur vs 6% #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

CROWN 7y update; #ASCO26 presentation by @TonyMok9 ; 34% dose reductions. Complex mechanisms of acqu resistance

[Dr Riyaz Shah @DrRiyazShah]

ALKOVE-1: phase 1/2; Neladalkib in ALK NSCKC; n781; good activity in treatment naïve; #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

AE and conclusions

[Dr Riyaz Shah @DrRiyazShah]

AcceleRET-LUNG: 1st line pralsetinib vs chemo;n233; 34% in chemo arm X’ed over. mPFS 9vs 18.7m HR 0.59, effect preserved in all subgroups; opportunistic infections an issue. #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

Lunbotinib in RET fusion +ve NSCLC; really active ASCO26

[Dr Riyaz Shah @DrRiyazShah]

OptiTROP-Lung05; sac-TMT + Pembro beats Pembro alone (6w) in PDL1 +ve NSCLC #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

Is this fundamentally a trail of maintenance anti-vascular MKI vs not? Analagous to lurbi in IMforte?

[Dr Riyaz Shah @DrRiyazShah]

FLAME; IIT F vs F2 …. Individualised escalation at 3w osi monotherapy if persistence ctDNA positivity; PFS 23.1m HR 0.54; OS NR HR 0.62; #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

NHS-Galleri; MCED: Randomised 140k people: Less stage 4; less emergency presentation; #ASCO26

[Dr Riyaz Shah @DrRiyazShah]

HLX43-FIH101; Anti PDL1 ADC; n205; 23%EGFR+; very preliminary data cORR 33% #ASCO26_lung

[Dr Riyaz Shah @DrRiyazShah]

ROSETTA Lung 02; active in both histologies across all pdl1 strata; #ASCO26_Lung